Media headlines about Syndax Pharmaceuticals (NASDAQ:SNDX) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.7543728974331 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Syndax Pharmaceuticals (SNDX) Releases Earnings Results, Beats Expectations By $0.13 EPS (americanbankingnews.com)
- Syndax Pharmaceuticals, Inc.’s (SNDX) CEO Briggs Morrison on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Syndax: 2Q Earnings Snapshot (finance.yahoo.com)
- Syndax Pharmaceuticals (SNDX) Reports Q2 Loss (finance.yahoo.com)
- Syndax Pharmaceuticals Inc (SNDX) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
NASDAQ:SNDX traded down $0.31 during mid-day trading on Friday, hitting $7.04. The stock had a trading volume of 205,962 shares, compared to its average volume of 290,200. The company has a market cap of $171.66 million, a PE ratio of -2.43 and a beta of 1.09. Syndax Pharmaceuticals has a 52 week low of $6.10 and a 52 week high of $15.20.
Several analysts recently weighed in on SNDX shares. HC Wainwright started coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, July 12th. They issued a “buy” rating and a $30.00 price objective on the stock. ValuEngine upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $25.20.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.